Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBI-101 in AKI with CRRT
NCT03015623Phase 2Unknown
- Sponsor
- Sentien Biotechnologies
- Start
- Jun 2017
- Primary completion
- Dec 2021
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SBI-101 in acute kidney injury (AKI) (3 arms), sponsored by Sentien Biotechnologies. Primary endpoint: Incidence of IP-related serious adverse events at Day 180. Status: unknown.
02
Drugs
SBI-101
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT03015623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015623.